Panacea Biotec liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

4.32×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.47×	1.47×	1.49×	1.57×	1.71×
0.92×	0.92×	0.90×	0.99×	1.09×
67.3	67.3	85.3	87.5	53.3
164	164	178	176	233

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PANACEABIO₹329.05

Panacea Biotec Limited

· Pharma & Health

₹ CrorePeersSAIPARENT HIKAL INDOCO DCAL WINDLAS HESTERBIO SOLARA SYNCOMFMcap ₹2,017 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	4.32
Current Ratio	1.71	1.57	1.49	1.47	1.47
Quick Ratio	1.09	0.99	0.90	0.92	0.92
Cash, Equiv & ST Investments	53.3	87.5	85.3	67.3	67.3
Working Capital	232.6	176.3	178.2	164.4	164.4

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.